WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Comprehensive Review on Combinational Antifungal and Antibacterial Drug Therapies: Advancing Treatment Strategies Against Resistant Infections

Milind Thakur[1], Ravinesh Mishra[2], Bhartendu Sharma[3]

[1]Research Scholar, School of Pharmacy and Emerging Sciences, Baddi University, Baddi, District-Solan, H.P.,India
[2]Associate Professor, School of Pharmacy and Emerging Sciences, Baddi University, Baddi, District-Solan, H.P.,India
[3]Associate Professor, School of Pharmacy and Emerging Sciences, Baddi University, Baddi, District-Solan, H.P.,India
Department of Pharmaceutics, School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences and technology, Baddi Makhnumajra- 173205, H.P. India

ABSTRACT

In order to address resistant infections and enhance patient outcomes, this review examines the idea of combinational therapy with an emphasis on antifungal and antibacterial medicines. Because of their invasiveness and the growing prevalence of drug-resistant types, bacterial and fungal diseases pose serious healthcare issues. Although bacterial infections are easier to treat than viral ones, managing bacteria is made more difficult by the emergence of antibiotic resistance. In a similar vein, fungal infections—especially opportunistic ones—present serious health hazards, particularly to individuals with weakened immune systems.

The mechanics and justification for fixed-dose combinations—which use several active components to provide synergistic effects, increase efficacy, and improve patient compliance—are covered in the review. Nevertheless, there are inherent difficulties, such as pharmacokinetic unpredictability, safety issues, and the possibility of harmful medication interactions.

Combinational treatments for bacteria and fungi are thoroughly investigated. Combination therapy for antibiotics can boost their efficacy against resistant bacteria, and it can be extremely important in emergency situations where the pathogen is unknown. In the meanwhile, antifungal combinations may work in concert to eradicate infections by acting on several pathways.

Along with their therapeutic uses, the study also lists a number of commercial formulations that mix antifungal and antibacterial drugs. It also discusses the difficulties and legal restrictions involved in creating successful combinational treatments, particularly in view of patent restrictions and the requirement for customized strategies to meet the needs of specific patient profiles.

Future directions highlight how combinational therapy might help patients overcome multidrug resistance, especially when clinical trials show how promising it is for different patient populations. The effectiveness of combination tactics may be further increased by integrating targeted medicines and sophisticated drug delivery technologies, opening the door for novel treatments in the ongoing fight against infectious illness.

Key words : Combinational drug therapy; Antibacterial resistance; Antifungal resistance; Fixed-dose combinations; Synergistic drug effects; Multidrug-resistant infections; Targeted drug delivery systems

INTRODUCTION

The fungal and becterial infections are very invasive some time and we need to cure it. Symptom of most bacteria and fungal infection was fever and it is regulated by hypothalamus , trigger of fever is called pyrogen.Antibacterial and Antifungal drugs function by blocking bacteria and from replicating and surviving . Penicillin as an antibacterial, for instance functions by inhibiting synthesis of bacteria cell walls[1,4].

Bacteria

Bacteria are organism that comes under unicellular prokaryotic microorganism they are neither plant or animal with similar metabolism as compared to eukarya and archaea. Scientist classify bacteria into major group according to characteristics such as shape ,size and structure[1].

Some are grow endospore in with condition of the environment which can survive nutrient depletion and germination with condition are more favourable.

Bacteria are main organism in environment which do nitrogen fixation by recycling the nutrients in environment. The earth holds about 5 nonillion bacteria they make earth biomass[1,2].

Bacterial infection are produce by small percentage of the world bacteria cause infection. But bacerial are much more easy to cure as compare to viruses .

A sufficient number of organisms must endure in the environment and make it to a vulnerable host in order to spread. Numerous bacteria have evolved to live in a variety of environments, including food, soil, and water. Before spreading to another person, some infect vectors like insects or animals. First, an organism's infectivity dictates number of people will come in contact it in relation to how many are exposed and susceptible. Second, an infectious organism's pathogenicity is a gauge of its capacity to spread illness. The traits of pathogenic bacteria enable them to use the body's resources and circumvent its defenses, resulting in illness. Last but not least, virulence refers to an organism's ability to spread illness by producing poisons and being invasive.[1,2]

The genetic material of bacteria, which are prokaryotic creatures, is stored in a double-stranded circular DNA molecule. Additionally, several organisms have tiny circular plasmids of extra DNA. Ribosomes are found in the cytoplasm of cells, and all species—aside from Mycoplasma—have a complex cell wall in addition to a cell membrane. Certain bacteria contain capsules, flagella, or pili outside of their cell walls (see Figure 1). Typically, bacteria multiply through binary fission. Certain bacteria have the ability to divide and grow quickly in the right circumstances. Because of this, certain infections can be potentially overwhelming with just a few organisms[2].



Fig 1

Epidemiology

The interaction between the bacterial agent and the host, which results in the acquisition of the infection, typically takes place in the external environment.

Humans can contract bacteria from food, water, the air, or live vectors. The propagation of germs can also be considered to be influenced by the macro- or microenvironments. Some environments, including prisons and hospitals, are home to particular kinds of species. In some geographical areas, certain bacteria are endemic, while in others, they are uncommon or nonexistent[2].

One essential component of modern medicine is the sensible use of antibiotics to treat bacterial illnesses. However, it should be emphasized that in many situations, the identification of the etiological bacterium and the assessment of its susceptibility to antibacterial medications do not allow for the

administration of antibiotics. This is particularly true in cases of acute bacterial infections, where delays may occur. In these situations, initial (non-targeted) antibiotic therapy is required. However, this does not meant that antibiotics should be administered carelessly; rigorous adherence to certain fundamental guidelines is required[3,4].

Fungus

In terms of categorization, fungi are unique organisms that belong to a different kingdom. Fungi are classified as eukaryotes because their cells are larger than those of bacteria, they have a membrane around their nucleus, and their molecular mechanisms are quite similar to those of plants and animals. Nevertheless, in contrast to mammalian cells, fungi nearly usually have a hard cell wall made of chitin products enclosing their plasma membrane (figure 2).

Despite being a vegetative organism, fungi are not considered plants because they do not produce chlorophyll. Its basic structure is either a unicellular form, a chain of cylindrical cells (hyphae), or both. It is a non-motile form. The most prevalent fungus that can cause fatal infections are Aspergillus and Candida, which are present all over the world [5].



Fig 2

Like all other living things, fungi are identified and recognized by their structures, forms, and behavioral characteristics. While those hyphal threads are referred to as molds, yeasts are fungi that mostly exist as independent single cells [6,7]. Human pathologic infections are often caused by a very small number of fungus [5].As saprophytic microbes, fungi have developed defenses against their mammalian hosts. Systemic fungal infections are uncommon and can have a high fatality rate; the majority of fungal infections have been unintentional.[6].

Fungal infection pathophysiology: There are number of fungi but out of them there few fungi which are harmful to humans are aggressive enough cause a infection in a healthy host. Unless the are come into contact with an immunocompromised patient, whose compromised defenses allow them to infiltrate the body, the majority are comparatively innocuous. Under normal conditions, the respiratory tract's mucociliary barrier and the gastrointestinal tract's attached to epithelial surfaces will prevent microbial invasion and the ambition of fungal cell and spores, respectively. There the damage and the dead tissue may become an infection breeding ground. Because of these factors, invasive fungal infections must be considered opportunistic infections.Although fungi are been identify as a plant diseases and a significant agricultural hazard, over the time they have developed into both primary and opportunistic infections that can infect both immunocompetent and immunocompromised people. Only 300 of the approximately 100,000 fungal species are known to infect humans or animals. Only a small number of fungal species (Candida spp.) can live in humans and animals; dermatophytes, for example, are extremely contagious and live in human and animal skin, hair, and nails. The majority of human fungal infections go undetected and are not adequately documented. The most prevalent fungal nfections iin humans are caused by dermatophytic fungi[5,6].

Combinational therapy

Combinations of two active or more active medications in a single dosage form are referred to as combination products, or fixed dose drug combinations (FDCs). "A product composed of any combination of a drug and a device or a biological product and a device or a drug and a biological product or a drug, device, and a biological product" is how the Food and Drug Administration, USA, defines a combination product[8,9].

Over the period 20 to 40 new drug were approved every year but about 6% of that are approved success rate and the therapies remain so complex and time-consuming and much costly for new strategies and new approaches and new technology are needed to extend new drug discovery and to improve the success rate of drug development.Certain factors, such as the fact that the medications in the combination should work through distinct processes, should serve as the foundation for the logic of FDCs.

• There shouldn't be significant variations in the pharmacokinetics.

• The components in the combination shouldn't be more poisonous than necessary.

The majority of FDCs have the following drawbacks:

• It is impossible to change the dosage of one medication without also changing the other.

• The issue of the formulation's frequency of administration is caused by the varying pharmacokinetics of its constituent medications.

• Compared to when both medications are administered separately, there is a logically higher possibility of negative pharmacological effects and interactions.

A significant combination treatment should meet a number of broad requirements. In order to prevent pharmacokinetic drug–drug interactions, the co-administered medications usually shouldn't alter each other's pharmacokinetic profiles[9].

The following issues can arise with FDCs that are not properly formulated:

(a) pharmacodynamic mismatch between the two components;

(b) pharmacokinetic mismatch and having peak efficacy at different times;

(c) chemical noncompatibility leading to longer shelf life;

(d) drug interactions due to common metabolizing pathways;

(e) limitations of finer dosing titration of individual ingredients.

(f) Despite being accessible in nearly every therapeutic category, many FDCs are odd pairings. Cough, cold, and fever preparations; analgesics and muscle relaxants; antimicrobials; medications for diabetes, hypertension, dyslipidemia, and mental illnesses; and vitamins and minerals are the therapeutic categories with the highest number of FDCs.Up to five or more substances, with justification or without justification for their presence and quantity, may be included in FDC formulation[10].

For a number of cardiovascular disorders, combination therapy including many medications is employed. Two well-known instances are pulmonary arterial hypertension and acute coronary syndrome. There are numerous studies show that combining two medicines from different classes might reduce essential hypertension in an additive manner[11,13].

Combining medications from two classes lowers blood pressure by a five times more than doubling the dosage of a single medication. This is especially true for thiazide diuretics, which combined with most, if not all, other kinds of medicines, greatly improve blood pressure control. Cardiac illness is frequently linked to other metabolic conditions such as diabetes, hypercholesterolemia; these conditions can be efficiently treated by combining several substances[11,12].

Antibiotics

Combination treatment (CT) is use of two or more antibiotics to treat a single infection. CT can be use to expand the antibiotic spectrum for microbial infections that are hard to treat, slow-growing, persistent, or highly drug-resistant, as well as illnesses with an unclear etiology.

CTs can have three main effects on the microorganisms: antagonistic, synergistic, and additive, which result in effects that are either the same as, more than, or less than the combined effects of the separate antibiotics[fig3][14].



Fig3

Pharmacological repositioning success rates can be raised by pharmacological combination therapy that has a synergistic impact. A phenotypic repurposing screen allows identification of new medicines from licensed medication collections without an understanding of the disease biology. Better illness therapies and a deeper comprehension of the complex pathophysiology of the disease may result from the discovery of efficient, synergistic medication combinations. For the numerous people suffering from uncommon diseases which have no treatments, drug repositioning offers hope[15].

In clinical settings where there is a high suspicion of bacterial infection, the consequences of not treating the condition are severe, and the possible infecting pathogen not able to identify, it is evidently fair to utilize combinations to increase coverage. Combinations should be used to limit or stop the formation of this resistance, particularly when it results from rare mutational events or from resistant bacterial subpopulations that are extremely rare in wild-type populations. This idea currently serves as the base for the application of antimicrobial combinations in a series of therapeutic scenarios[16].

These include using rifampin to treat mycobacterial infections, infections which caused by methicillin-resistant staphylococci, and infections which caused by some other resistant organisms[16].

Adv. of fixed Combination drug[17]

a) Improved Compliance:-

It would seem reasonable to assume that a fixed combination preparation will increase compliance if a patient requires multiple medicinal compounds.

b) Synergism :-

If the therapeutic impact of a fixed-ratio combination medication outweighs the additional effects of its constituents administered separately in the same dosage, the combination can always be justified. It allow use less drug concentration which reduce body chance of get toxicitiy.

c) Enhanced Efficacy :-

Even there is absence of genuine synergy, one drug's effectiveness may be increased by another's effect. According to 73% of US doctors, this is a key feature of combo medications.

d) Reduction of Side Effects

e) Increased Safety:-

Drugs will be safer to use if adverse effects are lessened, but proponents of fixed-ratio combinations point to a wider aspect of safety.

f) Decreased Potential for Abuse:

The narcotic antidiarrheal medication diphenoxylate is an example of how addictive drugs are occasionally used for quite modest objectives.

g) Reduced Cost:-

Calculations on the relative prices of fixed combination preparations and each of their constituent parts are intricate and differ between nations.

Disadvantages of Fixed Combination Drugs

a) Fixed-dose Ratio :-The loss of the doctor's flexibility in patient treatment is the main justifications against fixed dose combinations. The optimal dosage for many medications differs from patient to patient, and the dosage needs to be substantially customized in conditions like liver and renal failure. In certain conditions, such as depression with anxiety, the dosage must be changed while the patient is unwell.

b) Incompatible' Pharmacokinetics:- Co-trimoxazole is one example of a combination medication whose ingredients are specifically chosen to have comparable half-lives and clearance rates. Unfortunately, it is not the case for the majority of combinations, especially those that are older. In most cases, it may be assumed that two or more pharmacological components have distinct biologic half-lives (Levy, 1975). Significant variations in the patterns of drug pile may result from this.

c) Increased Toxicity:-Using two medications together will always raise that there is a possibility of idiosyncratic side effects rather than dose-related ones. It might be possible for the patient to identify the offender and engage in what Lasagna has dubbed "intelligent selective non-compliance" if specific medications are used. It goes without saying that combination medicines make this impossible.

d) Inappropriate Combinations:-Certain medication combos, such as barbiturates and analgesics or anti-inflammatory steroids and sedatives, are just illogical.

e) Physician and Pharmacist Ignorance of Content

f) Inappropriate Widening of the Target Population:-One potential issue with fixed combinations is that a patient might be prescribed and charged for one or more than one medications are unnecessary for the best possible management of their condition.

g) Imprecise Diagnosis and Treatmen and brand name and patent life

Antibacterial Combination Therapy

Combination therapy, aims to increase the antibacterial activity of well-known and efficient antibiotics, may help advance the clinical development of substances that were previously shown to be very effective but too harmful for the host. An additional benefit of this strategy is that it may result in shorter or lower dosage regimens, which could slow the rate at which infections develop resistance.[18]

The methods used to explain the minimum inhibitory concentration (MIC) is also use to determine the fractional inhibitory concentration (FIC). When the two drugs are combined, the MIC of each antibiotic is reduced four times compared to the MIC of each antibiotic tested alone, indicating that the antibiotic combination is synergistic. The time-killing curve method, which compares the action of each agent alone with the reduction of a fixed inoculum throughout a 24-hour exposure to combination antibiotics, is the alternative technique for identifying synergism. Synergism is defined as when the antibiotic combination's colony-forming units (cfu)/ml count for 24 hours is greater than or equivalent to a 2 log cfU/rnl reduction more than each agent alone.[19]

An aminoglycoside and an agent that prevents the formation of bacterial cell walls work together to produce a synergistic or neutral effect. Rarely, antagonism is observed, in the case of the penicillin-amikacin antagonism described above, which is observed against enterococci that generate APH(3'), which has amikacin-opposing action. Enterococci provide the most straightforward example of the typical synergistic interaction between aminoglycosides and cell-wall active drugs in vitro. Since the bacterial cell wall acts as a barrier to aminoglycoside uptake when it is intact, the mechanism of this synergism is fix to increased absorption of the aminoglycosides in the occupancy of an agent that breaks the cell wall[20].

Antifungal combinational therapy

Antifungal medications primarily work either directly or indirectly on the following sites fig 4(i) the cytoplasmic membrane (polyenes, azole)

(ii) the cell wall (echinocandins, nik-komycins);

(iii) the machinery involved in DNA and protein synthesis (flucytosine, sordarins). Combining medications that theoretically act at various places may eliminate fungal germs in a synergistic manner[21].

As with the less common fungi, analyses that respect these pathogens are more resilient and less vulnerable to the constraints imposed by the availability of only a few strains or single cases[22].

Studies assessing the effectiveness of antifungals in combination with antibacterial, anticancer, or immunomodulator drugs have been conducted in addition to antifungal-antifungal combos.

Since there aren't many of these exploratory investigations, they are summarized here, and readers who have a interested or urged to study the original publications[23].



fig: 4

Challenges in combinational therapy

Treatment of diseases with complicated aetiologies, which typically involve several targets and pathways, benefits greatly from the use of drug combinations. Despite the fact that occasionally, medication combinations do boost specificity'[24].

A key factor pushing the shift to combination therapies is the decrease in drug-level side effects; still in some cases, the effect of combination therapies is also influenced by the biological environment. Specifically, in vitro synergies may not result in in vivo combinations that work[25].

Drug combinations have many benefits, but it's important to comprehend their systemic effects, which are defined by the PD and PK of the separate medications and how they contact with one another[26].

- **Time dependent patients**

The effect of a chronic ailment, or the length of the treatment period, is ultimately the biggest obstacle to patient compliance, more so than the type of dose form. However, therapy can increase patient compliance by reducing the burden of pills.

Nevertheless, in order to achieve the optimum therapeutic results over a longer treatment duration, it is still crucial to construct treatment regimens with patient convenience and, consequently, compliance, in mind[27].

- **Inflixibility In dose**

Among the primary explanations why many prescribing physicians have been hesitant to fully embrace the use of Combination medication is that changes to individual components to decrease side effects or toxicity are not always practicable should the altered dose ratio not be available in an FDC product[27,28]

- **Development of a analytical method**

Determining several APIs may necessitate the use of sophisticated analytical techniques or the creation of novel analytical procedures, which can be expensive and time-consuming processes requiring specific knowledge and equipment[29].

- **Drug interaction**

When creating products, interactions between drugs and excipients are crucial factors to take into account. Bioavailability can be affected by drug-drug interactions, as is the case with isoniazid and rifampicin. Despite being a WHO-approved and advised combination, rifampicin has shown instability in the presence of isoniazid when exposed to an acidic environment, which reduced rifampicin's bioavailability[30,31].

Since steroids and anti-inflammatory drugs are known to alter the blood pressure, it should not be taken with anti-hypertensive treatments[32].

- **Fixed dose combination conflict with personal medicines precribed**

Due to variations in genetic profiles, race, gender, age, epigenetics, and environmental factors, treatment techniques must be customized to meet the needs of each patient. Treatment strategies must be tailored to each patient's weight, comorbidities, inter-patient tolerance, and therapy adverse effects. In this sense, a one-size-fits-all strategy is obsolete, and FDC therapy, which lacks dose flexibility, significantly undermines it[33].

One production technique which has been suggested for creating customized solid oral dose forms is additive manufacturing. Unquestionably, this technology is only appropriate for wealthier regions, and developing nations do not now have easy access to the highly specialized equipment[34,35].

- **Drug and patents hinder develop hinder develop of combinational therapy**

Combination products rarely contain novel molecular entities and frequently use APIs with expired patents. Depending on the patent status of each individual component meant to be included in the proposed product, product approval may be delayed. It has been known for pharmaceutical corporations to create and sell a product that includes an API whose patent is about to expire[27].

The goal of this approach is to prolong the API's patent and exclusivity period. In order to facilitate access to the suggested regimen, efforts are being made to remove items from single API patent constraints and instead establish a pharmaceuticals patent pool. Only a small number of products are approved through the Food and Drug Administration's (FDA) priority review process, while the majority of products have at least one patentable API[36].

Market formulation of combinational drug

Combining the both antibacterial and antifungal agents may enhance the treatment against infection involvind both types of pathogens. Several formulation combines various study have explored their effectiveness.[37-47]

S.no.	Combinational drug	Components	use
1.	Aceticacid and Hydrocortisone	Acetic acid (antibacterial & antifungal), hydrocortisone (anti-inflammatory)	Treats outer ear and ear canal infections
2.	TOL-463	Boric acid (antiseptic, antifungal), EDTA (antimicrobial enhancer)	Treats bacterial vaginosis and vulvovaginal candidiasis
3.	Clotrimazole and Neomycin Cream	Clotrimazole (antifungal), neomycin (antibacterial)	Treats mixed skin infections involving fungal and bacterial pathogens
4.	Miconazole and Polymyxin B Cream	Miconazole (antifungal), polymyxin B (antibacterial)	Treats mixed fungal and bacterial skin infections
5.	Nystatin and Tetracycline	Nystatin (antifungal), tetracycline (antibacterial)	eats oral infections like oral thrush with bacterial complications
6.	Ciprofloxacin and Fluconazole	Ciprofloxacin (antibacterial), fluconazole (antifungal)	Effective against mixed infections of bacterial and fungal origin
7.	Gentamicin and Clotrimazole	Gentamicin (antibacterial), clotrimazole (antifungal)	Topical cream for mixed skin infections
8.	Povidone-Iodine and Miconazole	Povidone-iodine (antiseptic with antibacterial & antifungal properties), miconazole	Vaginal pessary for mixed vaginal infections
9.	Amphotericin B and Rifampin	Amphotericin B (antifungal), rifampin (antibacterial)	Combination for systemic fungal and bacterial infections

10.	Ketoconazole and Chlorhexidine	Ketoconazole (antifungal), chlorhexidine (antibacterial)	Shampoo for fungal and bacterial scalp infections
11.	Silver Sulfadiazine and Miconazole	Silver sulfadiazine (antibacterial), miconazole (antifungal)	Cream for mixed infections in burn wounds

Future direction

Given the medications and treatment options available to address multidrug resistance in many infections and illnesses, combination therapy presents excellent prospects for the evolution of new medications in the 21st century. The strongest explanation for empirical antibiotic combinations is still the proven use of suitable antibiotic combinations to provide broad-spectrum coverage when the infectious organism is unknown and there is a very urgent need for therapy[48].The complexity of drug development is thought to rise when two or more drugs are combined and their pharmacokinetics and dynamics must match in order to sustain synergy. Naturally, the toxicity of each ingredient and the combination must be carefully examined before to clinical trials in case there are unforeseen drug-drug interactions.

For higher-order combinations there is more than two drugs are involved there is more complexity. One solution to this is the synthe- sis of single-agent hybrids that combine, in one molecule, the bioactive domains of each component[49].

A novel clinical strategy in the treatment in fungal infections is the application of antifungal combination therapy. Data now available clearly imply that combination therapy might benefit particular patient subgroups (such as recipients of stem cell transplants), despite the fact that few definate clinical studies have been conducted to yet. In order to identify workable clinical solutions for this exciting new therapeutic strategy, this paper analyzes the evidence from in vitro, experimental, and clinical trials[50,51].

Even though invasive fungal diseases are more common now than they were in the first half century, clinical diagnosis is still challenging. Many distinct classes of antifungal drugs have been identified in the other half of the century, especially in the last 20 years. Even though the science has advanced significantly since the discovery of amphotericin B, new antifungal medications are still desperately needed to treat invasive mycoses that pose a serious threat to human health[52].

Conclusion

Given the growing concerns about antibiotic resistance and the diversity of microbial pathogens, combinational therapy is a novel and promising strategy to the treatment of both antibacterial and antifungal illnesses. By increasing the antibacterial spectrum and possibly slowing the evolution of resistant strains, the combination of several pharmacological drugs can improve treatment efficacy. Given the shortcomings of current monotherapies, this approach enables medical professionals to treat polymicrobial infections more successfully, which is especially important.Combinational therapy has many benefits, but in order to maximize its clinical use, several important issues need to be resolved. Dosage concerns, pharmacokinetic and pharmacodynamic interactions, the possibility of elevated toxicity, and the difficulties associated with medication formulation are a few of these. Personalized treatment, which is becoming more and more important in treating varied patient populations with varying genetic profiles, comorbidities, and treatment responses, may be hampered by the rigidity frequently associated with fixed-dose combinations.

Future studies should concentrate on creating novel analytical techniques to precisely evaluate medication interactions and investigating the possibility of single-agent hybrids that combine the bioactive qualities of several different substances. Furthermore, additional clinical research is necessary to confirm the effectiveness of antifungal combination treatments, particularly in high-risk populations such individuals with impaired immune systems.Combinational therapy may be essential to improving treatment outcomes as the landscape of infectious illnesses continues to alter due to factors like environmental changes, globalization, and rising antibiotic resistance. New antifungal and antibacterial drugs are constantly being developed, and when combined with creative treatment plans, they have the potential to enhance patient outcomes by managing infections more successfully.

REFERENCES

1. Hungate Robert E., Halvorson Harly.O, Hutchison Keith, Orrego Cristian : Bacteria \ McGraw Hill Access Sciences Last reviewed: September 2023 https://doi.org/10.1036/1097-8542.068100
2. Doron, S., & Gorbach, S. L. (2008). Bacterial Infections: Overview. International Encyclopedia of Public Health, 273–282. doi:10.1016/b978-012373960-5.00596-7
3. Kolar Milan Bacterial Infections, Antimicrobial Resistance and Antibiotic Therapy Department of Microbiology, Faculty of Medicine and Dentistry, Palacký University Olomouc, 775 15 Olomouc, Czech Republic; milan.kolar@fnol.cz
4. Cole Laurence , karmer R Peter / Bacteria, Virus, Fungi, and Infectious Diseases Human Physiology, Biochemistry and Basic Medicine. 2015 Oct 30:193–196. 10.1016/B978-0-12-803699-0.00040-2

5. De Pauw, B. E. (2011). WHAT ARE FUNGAL INFECTIONS? Mediterranean Journal of Hematology and Infectious Diseases, 3(1), e2011001. DOI 10.4084/MJHID.2011.001

6. Ramana KV , Kandi Sabitha , Bharatkumar P Venkata, Sharada CH V, Rao Ratna , Mani Ratna, Rao Sanjeev D: Invasive Fungal Infections: A Comprehensive Review Received March 26, 2013; Revised June 10, 2013; Accepted June 24, 2013 DOI:10.12691/ajidm-1-4-2

7. Helwade Sakshi Dattatray, Shete Nikhil Arun, Ghawate V.B , Deshmukh V.K REVIEWON FUNGALINFECTION AND ANTIFUNG MEDICINAL PLANTS Publshed by DYPIPSR, Pimpri, Pune - 411 018 (MH) INDIA

8. Gautam, C. S., & Saha, L. (2008). Fixed dose drug combinations (FDCs): rational or irrational: a view point. British Journal of Clinical Pharmacology, 65(5), 795–796. doi:10.1111/j.1365-2125.2007.03089.x

9. Citation: Michel, M.C.; Staskin, D.Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit. Biomedicines 2022, 10, 270. https://doi.org/10.3390/biomedicines10020270

10. Gupta Y. K , Ramachandra S. s ;fixed dose drug combination issues and challenges in India EDITORIAL Indian J Pharmacol. 2016 Jul-Aug;48(4):347–349. doi: 10.4103/0253-7613.186200

11. Ascierto, P. A., & Marincola, F. M. (2011). Combination therapy: the next opportunity and challenge of medicine. Journal of Translational Medicine, 9(1), 115. doi:10.1186/1479-5876-9-115

12. Wald, D. S., Law, M., Morris, J. K., Bestwick, J. P., & Wald, N. J. (2009). Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. The American Journal of Medicine, 122(3), 290–300. doi:10.1016/j.amjmed.2008.09.038

13. Mukherjee, B., & Howard, L. (2011). Combination therapy in pulmonary arterial hypertension: do we have the right strategy? Expert Review of Respiratory Medicine, 5(2), 191–205. doi:10.1586/ers.11.13

14. Sullivan, G. J., Delgado, N. N., Maharjan, R., & Cain, A. K. (2020). How antibiotics work together: molecular mechanisms behind combination therapy. Current Opinion in Microbiology, 57, 31–40. doi:10.1016/j.mib.2020.05.012

15. Sun, W., Sanderson, P. E., & Zheng, W. (2016). Drug combination therapy increases successful drug repositioning. Drug Discovery Today, 21(7), 1189–1195. doi:10.1016/j.drudis.2016.05.015

16. Moellering, R. C. (1983). Rationale for use of antimicrobial combinations. The American Journal of Medicine, 75(2), 4–8. doi:10.1016/0002-9343(83)90088-8

17. Shenfield G.M ,Fixed Combination Drug Therap;Department of Clinical Pharmacology, Royal North Shore Hospital, Sydney.

18. Cottarel, G., & Wierzbowski, J. (2007). Combination drugs, an emerging option for antibacterial therapy. Trends in Biotechnology, 25(12), 547–555. doi:10.1016/j.tibtech.2007.09.004.

19. Rybak M.J and McGrath Combination Antimicrobial Therapy for Bacterial Infections Guidelines for the Clinician ;Drugs 1996 Sap; 52 (3): 390-4050012-6667/96/0CXYI-039O/S 16.00/0 Adis InternatIonal Limited.

20. ROBERT C. MOELLERING, Jr., M.D Rationale for Use of Antimicrobial Combinations;New England Deaconess Hospital. Boston,Massachusetts.

21. Baddley J.H and Pappas P.G;Antifungal Combination Therapy Clinical Potential; Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA Birmingham Veteran's Administration Medical Center, Birmingham, Alabama, USA

22. Johnson M.D , MacDougall .C, Zeicher.L.O,Perfect.J.R and Rex J.H; Combination Antifungal Therapy A NTIMICROBIAL A GENTS AND C HEMOTHERAPY , Mar. 2004, p. 6932715 0066-4804/04/$08.0010 DOI: 10.1128/AAC.48.3.693–715.200.

23. Mukherjee.P.K,SheehanD.J,Hitchcock.C.A,andGhannoum.M.A;Combination Treatment of Invasive Fungal Infections CLINICAL MICROBIOLOGY REVIEWS,Jan.2005,p.16319408938512/05/$08.000doi:10.1128/CMR.18.1.163–194.2005

24. Leha´r, J. et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659–666

25. Mott, B.T. et al. (2015) High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Sci. Rep. 5, 11389http:// dx.doi.org/10.1038/srep13891

26. Bulusu, K. C., Guha, R., Mason, D. J., Lewis, R. P. I., Muratov, E., Kalantar Motamedi, Y., … Bender, A. (2016). Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discovery Today, 21(2), 225–238. doi:10.1016/j.drudis.2015.09.003

27. Wilkins, C.A.; Hamman, H.; Hamman, J.H.; Steenekamp, J.H. Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features. Pharmaceutics 2024, 16, 178. https://doi.org/10.3390/pharmaceutics16020178.

28. Webster, R.; Patel, A.; Selak, V.; Billot, L.; Bots, M.L.; Brown, A.; Bullen, C.; Cass, A.; Crengle, S.; Raina Elley, C.; et al. Effectiveness of □xed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data

29. Chen, L.; Chen, J.; Lu, M.; Stämp□i, A. Simultaneous determination of elbasvir and grazoprevir in □xed-dose combination and mass spectral characterization of each degradation product by UHPLC-ESI-QTOF-MS/MS. J. Pharm. Biomed. Anal. 2020, 178, 112964 meta-analysis of 3140 patients in six countries. Int. J. Cardiol. 2016, 205, 147–156.

30. Bhutani, H.; Mariappan, T.T.; Singh, S. The physical and chemical stability of anti-tuberculosis □xed-dose combination products under accelerated climatic conditions. Int. J. Tuberc. Lung Dis. 2004, 8, 1073–1080.

31. Bhutani, H.; Singh, S.; Jindal, K.C.; Chakraborti, A.K. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. J. Pharm. Biomed. Anal. 2005, 39, 892–899.

32. Elliott, W.J. Drug interactions and drugs that affect blood pressure. J. Clin. Hypertens. 2006, 8, 731–737.

33. Oyewumi, M. 3D Printing Technology in Pharmaceutical Drug Delivery: Prospects and Challenges. J. Biomol. Res. Ther. 2015, 4.

34. Jakka, S.; Rossbach, M. An economic perspective on personalized medicine. Hugo J. 2013, 7, 1.

35. Goetz, L.H.; Schork, N.J. Personalized medicine: Motivation, challenges, and progress. Fertil. Steril. 2018, 109, 952–963.

36. Hao, J.; Rodriguez-Monguio, R.; Seoane-Vazquez, E. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. PLoS ONE 2015, 10, e0140708

37. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 24847774, Hydrocortisone/Acetic acid. Retrieved January 6, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/Hydrocortisone_Acetic-acid.

38. Marrazzo, J. M., Dombrowski, J. C., Wierzbicki, M. R., Perlowski, C., Pontius, A., Dithmer, D., & Schwebke, J. (2018). Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clinical Infectious Diseases. doi:10.1093/cid/ciy554

39. Kiran .M, Pawaskar.L,Waghambare.P, Sheikh.S. Efficacy and Safety for the Combination of Neomycin,Beclomethasone, Clotrimazole and Lignocaine for the Treatment of Otitis Media with Perforation and Otitis Externa: Post-Marketing Surveillance Study DOI:10.18535/ijmsci/v8i07.05

40. Pietschmann, S., Meyer, M., Voget, M., & Cieslicki, M. (2013). The jointin vitroaction of polymyxin B and miconazole against pathogens associated with canine otitis externa from three European countries. Veterinary Dermatology, 24(4), 439–e97. doi:10.1111/vde.12037

41. YOUNGER, D., EPIFANO, L. D., DIPILLO, F., HOFFMAN, I., THALER, E., & YARVIS, M. (1959). A clinical comparison of the side effects of tetracycline-nystatin and tetracycline. Antibiotic medicine & clinical therapy (New York, NY), 6(4), 216–221.

42. Berger FA, Monadian N, de Groot NMS, Santbergen B, van der Sijs H, Becker ML, Broers AEC, van Gelder T, van den Bemt PMLA. QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors. Br J Clin Pharmacol. 2018 Feb;84(2):369-378. doi: 10.1111/bcp.13457. Epub 2017 Dec 6. PMID: 29057492; PMCID: PMC5777440.

43. Hojyo T. (1987). Combination dermatological products: a comparison of betamethasone dipropionate/clotrimazole/gentamicin sulphate and flumethasone pivalate/clioquinol creams. The Journal of international medical research, 15(5), 255–263. https://doi.org/10.1177/030006058701500501

44. Sethi N. C. (1983). Comparative Study of Econazole and Povidone Iodine (betanide) in Management of Dermatophytosis. Indian journal of dermatology, venereology and leprology, 49(3), 102–105.

45. Christenson JC, Shalit I, Welch DF, Guruswamy A, Marks MI. Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrob Agents Chemother. 1987 Nov;31(11):1775-8. doi: 10.1128/AAC.31.11.1775. PMID: 3435124; PMCID: PMC175037.

46. Shino B, Peedikayil FC, Jaiprakash SR, Ahmed Bijapur G, Kottayi S, Jose D. Comparison of Antimicrobial Activity of Chlorhexidine, Coconut Oil, Probiotics, and Ketoconazole on Candida albicans Isolated in Children with Early Childhood Caries: An In Vitro Study. Scientifica (Cairo). 2016;2016:7061587. doi: 10.1155/2016/7061587. Epub 2016 Mar 14. PMID: 27051559; PMCID: PMC4808662.

47. Mohan M, Gupta SK, Kalra VK, Vajpayee RB, Sachdev MS. Topical silver sulphadiazine--a new drug for ocular keratomycosis. Br J Ophthalmol. 1988 Mar;72(3):192-5. doi: 10.1136/bjo.72.3.192. PMID: 3281706; PMCID: PMC1041404.

48. FOHRER, C., FORNECKER, L., NIVOIX, Y., CORNILA, C., MARINESCU, C., & HERBRECHT, R. (2006). Antifungal combination treatment: a future perspective. International Journal of Antimicrobial Agents, 27, 25–30. doi:10.1016/j.ijantimicag.2006.03.016

49. Malik, M. A., Wani, M. Y., & Hashmi, A. A. (2020). Combination therapy: Current status and future perspectives. Combination Therapy Against Multidrug Resistance, 1–38. doi:10.1016/b978-0-12-820576-1.00001-1

50. Rahman M, Islam F, Rahman A, Ahmed T, Uddin MB, Shaheen SM, Khushi SY. Present and future prospect of combination drugs therapy. World Journal of Pharmaceutical Research. 2020 Jan 19;9(3):1625-38.

51. Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell stem cell, 2015 Jul 2; 17(1): 11-22.

52. Andriole, V. T. (1999). Current and future antifungal therapy: new targets for antifungal agents. Journal of Antimicrobial Chemotherapy, 44(2), 151–162. doi:10.1093/jac/44.2.151